Acer Therapeutics Expands ACER-801 Development Into Post-Traumatic Stress Disorder
Acer Therapeutics Inc (NASDAQ:ACER) expanded ACER-801 (osanetant) into a new indication for the reduction of the frequency and severity of acute…
Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids
The FDA has accepted Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) supplemental marketing application for the potential expanded use of TAKHZYRO (lanadelumab-flyo) for…
Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer’s Trial
Alzamend Neuro Inc (NASDAQ:ALZN) has dosed its first healthy adult subject in its Phase 2A multiple ascending dose (MAD) study of…
Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study
Eliem Therapeutics Inc (NASDAQ:ELYM) announced interim results from its ongoing Phase 1 trial of ETX-155 for major depressive disorder (MDD) and…
Eiger BioPharma Shuns Plans For FDA Emergency Use Nod For COVID-19 Treatment
Following FDA feedback, Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) will not submit an emergency use authorization (EUA) application of peginterferon lambda for mild-to-moderate COVID-19.…
Russian Gas Firm Gazprom Resumes Gas Deliveries To Italy Via Austria
Russian gas giant Gazprom is resuming transportation of Russian gas to Italy via Austria, saying a necessary solution was reached with the Italian buyers for the gas flow.
E-Cigarette Maker Juul Mulls Potential Bankruptcy
Juul Labs Inc, backed by Altria Group Inc (NYSE: MO), has been exploring various options—including bankruptcy—after the FDA issued its marketing denial order.
Sight Sciences’ Near-Term Upside Is Limited, Says This Analyst
Needham initiated coverage on Sight Sciences Inc (NASDAQ:SGHT) with a Hold rating and no price target. The analyst warns that the recent competitive…
Needham Says Recent Launches To Drive Market Share Recovery For This Eye-Focused MedTech Stock
Needham initiated coverage on Glaukos Corp (NYSE:GKOS) with a price target of $66 and a Buy rating. The analyst writes that GKOS has…
Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO’s Price Target
On Monday, REGENXBIO Inc (NASDAQ:RGNX) announced a program update from its ongoing clinical investigation of RGX-314 for wet AMD, a leading cause…